NextPlat (NASDAQ:NXPL) Announces Earnings Results

NextPlat (NASDAQ:NXPL) announced its quarterly earnings results on Thursday. The company reported ($0.42) earnings per share for the quarter, Zacks reports. NextPlat had a negative net margin of 21.56% and a negative return on equity of 53.22%.

Here are the key takeaways from NextPlat’s conference call:

• NextPlat said its turnaround is largely complete, with Q1 showing record-level gross margins, lower operating expenses, and a clear path to improving profitability in the second half of 2026.
• The healthcare segment posted a major improvement, with gross margin rising to 39% from about 20% a year ago and the segment generating positive operating income for the quarter.
• The company secured five new 340B pharmacy service agreements in the quarter, a record, and expects those customers to begin contributing to revenue in the third quarter after onboarding.
• Management highlighted new growth initiatives, including a nationwide fulfillment partnership and a planned e-commerce healthcare site that will sell prescription drugs, GLP-1 products, and OTC items, expected to launch before the end of Q2.
• Quarterly revenue declined year over year to about $10 million, though the company said the mix is shifting toward higher-margin contract and fulfillment revenue, while e-commerce remained steady at about $3.2 million.

NextPlat Stock Down 2.3%

Shares of NXPL traded down $0.15 during mid-day trading on Thursday, reaching $6.26. 16,641 shares of the stock traded hands, compared to its average volume of 12,016. The firm has a market cap of $16.96 million, a price-to-earnings ratio of -1.42 and a beta of 1.91. The stock has a fifty day simple moving average of $5.42 and a 200 day simple moving average of $6.07. NextPlat has a 12-month low of $3.38 and a 12-month high of $11.10. The company has a quick ratio of 2.27, a current ratio of 2.65 and a debt-to-equity ratio of 0.05.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of NextPlat from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Institutional Trading of NextPlat

A hedge fund recently bought a new stake in NextPlat stock. Citadel Advisors LLC acquired a new stake in shares of NextPlat Corp. (NASDAQ:NXPL) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 48,176 shares of the company’s stock, valued at approximately $40,000. Citadel Advisors LLC owned 0.19% of NextPlat as of its most recent SEC filing. 1.30% of the stock is currently owned by institutional investors.

About NextPlat

NextPlat Corp operates as a healthcare and e-commerce company in Europe, North America, South America, the Asia and Pacific, and Africa. The company operates full-service retail specialty services pharmacies that provides prescription pharmaceuticals prescription pharmaceuticals, third-party administration, risk and data management services, compounded medications, tele-pharmacy services, anti-retroviral medications, medication therapy management, contracted pharmacy services, and health practice risk management to healthcare organizations and providers, as well as supplies prescription medications to long-term care facilities.